The FDA approves the first AI tool to predict the risk of breast cancer

The United States Drug and Food Administration (FDA) has approved the first artificial intelligence (AI) tool to predict the risk of breast cancer.

The authorization was confirmed by the Clairity Digital Health Technology Company, the Clairity Breast developer, a new prognosis platform based on images designed to predict the risk of five -year breast cancer from a routine detection mammogram.

In a press release, Clairity shared his plans to launch the AI ​​platform in health systems until 2025.

AI detects ovarian cancer better than human experts in a new study

Most risk assessment models for breast cancer depend largely on age and family history, according to Clairity.

However, about 85% of cases occur in women who have no family history of breast cancer, probably derived from genetic mutations that occur due to aging, they inform health agencies.

Traditional risk models have also been based on data from predominantly European Caucasian women, which Clairity said it has not been “well widespread” to various origins.

The AI ​​tool analyzes subtle images of a detection mammogram that correlates with the risk of breast cancer, then generates a “validated five -year risk score” and delivery to medical care providers, the company said.

AI detects women’s breast cancer after the detection of routine that was lost: ‘deeply grateful’

Dr. Connie Lehman, founder of Clairity and specialist in Mama images at Mass Brigham General, emphasized the importance of mammograms in the early detection of cancer.

“Now, advances in AI and computer vision can discover hidden clues in mammograms, invisible to the human eye, to help predict future risk,” he said in a press release.

“When delivering validated and equitable risk assessments, we can help expand access to early detection and prevention that save life for women everywhere.”

Click here to get the News application

Dr. Robert A. Smith, senior vice president of early cancer detection in the American Cancer Society, also commented on a statement that the personalized and risk -based examination is “critical to improve the results of breast cancer, and AI tools offer us the best opportunity to meet that potential.”

“This is the wave of the future. AI will be part of the equation, but it will not take care.”

“The authorization of the FDA of Clairity is a turning point for more women to access the scientific advances of the Cancer Risk Promoted by AI,” wrote Larry Norton, founding scientific director of the Breast Cancer Research Foundation, in another statement.

“Breast cancer is increasing, especially among younger women, however, most risk models often miss those who will develop the disease,” he said. “Now we can make sure that more women get adequate attention at the right time.”

More than 2.3 million women are diagnosed with breast cancer worldwide every year, including more than 370,000 in the US, despite the “decades of progress”, according to the breast cancer research foundation.

Cases have increased particularly among young women under 50 years.

Click here to register in our health newsletter

In an appearance on Tuesday in “America’s Newsroom”, News senior medical analyst, Dr. Marc Siegel, described the development of Clairity “Profound.”

“Just looking at a mammogram … sometimes [radiologists] You will see things that are not clear, they have to follow him over time, “he said.” The improvement how focused and the predictive is, [shown] very dramatically in studies. “

Siegel confirmed that radiologists from all over the country generally support AI for cancer detection, especially in areas of the country that are “unattended” in terms of medical care.

For more health articles, visit www.Newsnews.com/health

“In areas where he trusted radiologists without special training, this is even more important,” he said.

“This is the wave of the future. AI will be part of the equation, but it will not take care.”